血浆miRNA特征谱区分单发与多发甲状旁腺疾病的初步研究
该初步研究纳入47例散发性原发性甲状旁腺功能亢进症(sPHPT)患者(单发甲状旁腺腺瘤32例、双发腺瘤12例、多腺体病变9例),并对16例单发腺瘤患者与29名健康供者的术前血浆行2083种miRNA检测。组织与血浆数据整合得到27个miRNA在单发腺瘤中差异表达,其中9个循环游离miRNA(cfmiR)特征在组织和血浆中均差异表达(AUC=76%),作者认为其有望用于术前诊断单发腺瘤所致的sPHPT。
要点
- 47例sPHPT患者中单发腺瘤32例、双发腺瘤12例、多腺体病变9例
- 血浆分析纳入16例单发腺瘤患者与29名健康供者
- 9个cfmiR特征在组织和血浆中均差异表达,AUC=76%
核心结论
- 27个miRNA在单发甲状旁腺腺瘤组织和血浆样本中持续差异表达;数据整合显示9个cfmiR特征具有术前诊断单发腺瘤所致sPHPT的潜在临床价值,可能减少更具侵袭性的甲状旁腺探查。
研究设计与样本
- 初步研究,纳入47例sPHPT患者(单发腺瘤32例、双发腺瘤12例、多腺体病变9例),并对16例单发腺瘤患者与29名健康供者的术前血浆进行分析。
- 采用HTG EdgeSeq miRNA全转录组检测2083种miRNA,以DESeq2归一化识别差异表达miRNA,并用随机森林建立miRNA分类器,主要结局指标为受试者工作特征曲线及曲线下面积。
主要发现
- miRNA特征可区分正常甲状旁腺与多腺体病变、甲状旁腺腺瘤,也可在组织样本中区分多腺体病变与甲状旁腺腺瘤。
- 单发腺瘤与双发腺瘤组织中存在共同的miRNA;与其余组织样本相比,单发腺瘤组织样本中识别出27个miRNA特征。
- 血浆样本分析中,与健康供者相比,单发腺瘤患者存在显著差异表达的cfmiR;其中仅9个miRNA/cfmiR在单发腺瘤患者的组织和血浆样本中均差异表达(AUC=76%)。
关键数值与推荐
- 单发腺瘤患者组织和血浆中均差异表达的9个miRNA/cfmiR特征AUC=76%。
- 单发腺瘤组织样本中识别出27个miRNA特征。
- 检测覆盖2083种miRNA。
临床怎么用
- 作者认为,9个cfmiR特征具有术前诊断单发腺瘤所致sPHPT的潜在临床价值,可能减少更具侵袭性的甲状旁腺探查。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The ability to differentiate sporadic primary hyperparathyroidism (sPHPT) caused by a single parathyroid adenoma (PTA) from multiglandular parathyroid disease (MGD) preoperatively, as well as definitely diagnose sPHPT in difficult patients, would enhance surgical decision-making. OBJECTIVE: This work aimed to identify miRNA (miR) signatures for MGD, single- and double-PTA, as well as cell-free miRNA (cfmiR) in plasma samples from patients with single-PTAs to use as biomarkers. METHODS: A total of 47 patients with sPHPT (single-PTA n = 32, double-PTA n = 12, MGD n = 9). Preoperative plasma samples from 16 single-PTA and 29 normal healthy donors (NHDs). All specimens were processed and analyzed for 2083 miRs using HTG EdgeSeq miR whole-transcriptome assay and normalized using DESeq2 to identify differentially expressed (DE) miRs. MiR classifiers were identified using Random Forest. Main outcome measures were receiver operating characteristic curves and areas under the curve. RESULTS: MiR signatures distinguished normal parathyroid from MGD and PTA as well as MGD from PTA in tissue samples. Common miRs were found in the single-PTA and double-PTAs. Data integration identified a 27-miR signature in single-PTA tissue samples compared to the rest of the tissue samples. In plasma samples analysis, significant cfmiRs were DE in single-PTA patients compared to NHD. Of those, only 9 miRNAs/cfmiRs were found DE both in tissue and plasma samples from patients diagnosed with a single PTA (AUC = 76%). CONCLUSION: Twenty-seven miRs were consistently found DE in single-PTA tissue and plasma samples. Data integration showed a 9-cfmiR signature with potential clinical utility to preoperatively diagnose sPHPT caused by a single PTA, which could decrease more invasive parathyroid explorations.
引用
- Goldfarb M, Bustos MA, Moon J, et al. Pilot Study of Plasma miRNA Signature Panel for Differentiating Single vs Multiglandular Parathyroid Disease. J Clin Endocrinol Metab. 2025. PMID: 39163258. doi:10.1210/clinem/dgae577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。